Alnylam Pharma (ALNY) Tops Q3 EPS by 21c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/20/2026

1. SPY
2. XENE
3. HUBS
4. NUE
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to Alnylam Pharma (ALNY) Tops Q3 EPS by 21c

JPMorgan Upgrades Alnylam Pharmaceuticals (ALNY) to Overweight

November 9, 2017 4:37 AM EST

JPMorgan upgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Neutral to Overweight with a price target of $162.00 (from $86.00).

Analyst Anupam Rama believes givosiran remains underappreciated on the Street and as a driver of upside for the company. The analyst also is expecting a smooth... More

Alnylam Pharmaceuticals (ALNY) PT Raised to $158 at Barclays on 3Q Report; 'Multiple Programs Progressing to Approval/Late-Stage Development'

November 8, 2017 11:54 AM EST

Barclays raised its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $158.00 (from $127.00) while maintaining a Overweight rating, following the company's third quarter earnings report.

Analyst Gena Wang notes a positive outlook on the shares, as the company reported third quarter earnings per share results above... More

Alnylam Pharmaceuticals (ALNY) PT Raised to $107 at Stifel

November 8, 2017 10:07 AM EST

Stifel raised its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $107.00 (from $83.00) while maintaining a Hold rating following non-eventful earnings.

Analyst Stephen Willey views the initiation of the P3 ENVISION trial as an incremental positive.

... More